个体化直接口服抗凝药治疗:种族、肾功能、药物相互作用与药物基因组学的作用
本文综述影响直接口服抗凝药(DOAC)反应变异性的因素,包括年龄、性别、体重、肾功能、药物相互作用和药物基因组学。作者指出DOAC随机对照试验未充分纳入不同 ancestry 人群,现有药物遗传学证据主要来自欧洲和亚洲个体,呼吁未来研究纳入多样人群以量化和推广预测因素的影响。
要点
- DOAC已取代华法林成为房颤和静脉血栓栓塞预防的首选口服抗凝药。
- DOAC反应变异性常见,与患者因素、合并用药、合并症和遗传有关。
- 现有证据不足以在不同种族人群中推广临床和遗传因素对DOAC变异性的影响。
核心结论
- DOAC反应变异性受年龄、性别、体重、肾功能、药物相互作用和药物基因组学等多因素影响。
- 当前证据主要来自欧洲和亚洲人群,需在多样人群中进一步研究以量化预测因素的影响。
研究设计与样本
- 综述文章,讨论影响DOAC反应的因素并提出未来研究方向。
- 未报告系统检索范围或纳入研究的样本量。
主要发现
- DOAC随机对照试验纳入不同年龄和肾功能水平的患者,但未纳入不同 ancestry 的人群。
- 支持DOAC药物遗传学关联的证据主要来自欧洲和亚洲个体。
- 不同生物地理人群的基因型频率和疾病负担存在差异。
临床怎么用
- 临床应综合考虑年龄、性别、体重、肾功能、药物相互作用和遗传因素评估DOAC反应变异。
- 关注不同种族人群在DOAC反应预测因素上的证据不足问题。
局限性
- 现有研究未充分纳入不同种族人群,限制临床和遗传因素对DOAC变异性影响的推广。
- 药物遗传学证据主要来自欧洲和亚洲个体,缺乏其他人群数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Oral anticoagulants (OACs) are commonly used to reduce the risk of venous thromboembolism and the risk of stroke in patients with atrial fibrillation. Endorsed by the American Heart Association, American College of Cardiology, and the European Society of Cardiology, direct oral anticoagulants (DOACs) have displaced warfarin as the OAC of choice for both conditions, due to improved safety profiles, fewer drug-drug and drug-diet interactions, and lack of monitoring requirements. Despite their widespread use and improved safety over warfarin, DOAC-related bleeding remains a major concern for patients. DOACs have stable pharmacokinetics and pharmacodynamics; however, variability in DOAC response is common and may be attributed to numerous factors, including patient-specific factors, concomitant medications, comorbid conditions, and genetics. Although DOAC randomized controlled trials included patients of varying ages and levels of kidney function, they failed to include patients of diverse ancestries. Additionally, current evidence to support DOAC pharmacogenetic associations have primarily been derived from European and Asian individuals. Given differences in genotype frequencies and disease burden among patients of different biogeographic groups, future research must engage diverse populations to assess and quantify the impact of predictors on DOAC response. Current under-representation of patients from diverse racial groups does not allow for proper generalization of the influence of clinical and genetic factors in relation to DOAC variability. Herein, we discuss factors affecting DOAC response, such as age, sex, weight, kidney function, drug interactions, and pharmacogenetics, while offering a new perspective on the need for further research including frequently excluded groups.
引用
- Thompson LE, Davis BH, Narayan R, et al. Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics. Clin Pharmacol Ther. 2022. PMID: 35857814. doi:10.1002/cpt.2714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。